Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resolution Enhancement by Venoruton for Eight Weeks in Deep Vein Thrombosis
2020-000749-15Phase 3Completed
- Sponsor
- Maastricht University Medical Center+
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of hydroxyethylrutoside in deep vein thrombosis (DVT) and post-thrombotic syndrome (PTS), sponsored by Maastricht University Medical Center+. Primary endpoint: Presence of residual venous obstruction. Started May 2020; status: completed.
02
Drugs
hydroxyethylrutoside
03
Conditions
deep vein thrombosis (DVT)post-thrombotic syndrome (PTS)
Beyond the preview
Go deeper on 2020-000749-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000749-15.